| Toggle Summary
|
Stockholders Approve All Proposals at Galectin Therapeutics' Annual Stockholders Meeting
Judge Paul Pressler Elected to the Board of Directors
|
View HTML
|
| Toggle Summary
|
Pro-Pharmaceuticals Changes Company Name to Galectin Therapeutics
New Name Highlights Company's Scientific Expertise in Galectins Applied to the Treatment of Serious Diseases Such as Fibrosis and Cancer
|
View HTML
|
| Toggle Summary
|
Pro-Pharmaceuticals to Hold Conference Call to Provide Update Following Company's Annual Meeting of Stockholders
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS' PRESENTATION AT NOBLE FINANCIAL CAPITAL MARKETS' SEVENTH ANNUAL EQUITY CONFERENCE TO BE WEBCAST LIVE
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS SELECTS SAFC® TO RAMP-UP THE MANUFACTURE OF DAVANAT® FOR ANTICIPATED USE IN CLINICAL TRIALS & SALES IN COLOMBIA
|
View HTML
|
| Toggle Summary
|
Pro-Pharmaceuticals Expands Patent Coverage to Japan
Patent Covers Use of DAVANAT® with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments
|
View HTML
|
| Toggle Summary
|
THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS DISCOVER THAT DAVANAT® ENHANCES THE ABILITY OF ANTITUMOR T LYMPHOCYTES TO KILL TUMOR CELLS
Pro-Pharmaceuticals' DAVANAT® Targets Galectin Proteins Secreted by Cancer Cells and Eliminates The Cancer's Ability to Evade the Immune System
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH NEW PATENTS IN THE U.S. AND AUSTRALIA
Patents Cover Use of DAVANAT® with Chemotherapy to Increase Effectiveness and Reduce Side Effects of Cancer Treatments
|
View HTML
|
| Toggle Summary
|
PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2010 FINANCIAL RESULTS
|
View HTML
|
